What is Sun Pharma Advanced Research Company Ltd (SPARC) share price return in the past 10 years?

Sun Pharma Advanced Research Company Ltd share price has declined -2.6% annually (CAGR) over the past ten years.

What is the share price of Sun Pharma Advanced Research Company Ltd (SPARC)?

Company share prices are keep on changing according to the market conditions. The current trading price of Sun Pharma Advanced Research Company Ltd (SPARC) on 04-Jun-2026 16:59:59 at 16:59 is 212.90.

What is the P/E ratio of Sun Pharma Advanced Research Company?

The latest standalone P/E ratio of Sun Pharma Advanced Research Company as of 04-Jun-2026 is 4.45.

What is the P/B ratio of Sun Pharma Advanced Research Company Ltd (SPARC)?

The latest standalone P/B ratio of Sun Pharma Advanced Research Company Ltd (SPARC) as of 04-Jun-2026 is 5.18.

What is the 52-week high and low of Sun Pharma Advanced Research Company Ltd (SPARC)?

The 52-week high of Sun Pharma Advanced Research Company Ltd (SPARC) is Rs. 248.65 and the 52-week low is Rs. 108.20.

Sun Pharma Advanced Research Company Ltd (SPARC) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Sun Pharma Advanced Research Company Ltd (SPARC)
Brand: Sun Pharma Advanced Research Company

Key Metrics

Valuation Multiples

Market Cap

₹6,909 Cr.

Current Price

₹212.9

52-Week Low / High

₹108 / 249

TTM EPS

₹47.8

TTM Sales

₹39.2 Cr.

Book Value per Share

₹41.1

P/E Ratio

4.45

Industry PE

Price to Book (P/B)

5.18

Higher than its 5-year historical median

Price to Sales (P/S)

176.48

Higher than its 5-year historical median

EV/EBITDA

4.64

Higher than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

0.00%

Underperforms industry median

Return on Capital Employed (ROCE)

-321.18%

Underperforms industry median

Return on Assets (ROA)

-84.65%

Operating Profit Margin

-453.6%

Net Profit Margin

-481.04%

Gross Profit Margin

-466%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

-5%

Operating Profit Growth (1 Year)

Net Profit Growth (1 Year)

Asset Quality

Promoter Holding

65.67%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹1,301 Cr.

Equity

₹32.5 Cr.

Face Value

₹1

All Time Low / High

₹38.44 / 593.93

Sun Pharma Advanced Research Company stock performance

Key Ratios

Check Before You Invest

Quality

Not Good

Check detailed performance

Valuation

Overvalued

Check Valuation charts

Price Trend

Strong

Check Price chart

Q.1 Is Sun Pharma Advanced Research Company Ltd a good quality company?

Sun Pharma Advanced Research Company Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Sun Pharma Advanced Research Company Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Sun Pharma Advanced Research Company Ltd vs industry peers?

Sun Pharma Advanced Research Company Ltd revenue CAGR is -1.35%, compared to the industry median CAGR of 0.35%, indicating slower growth and losing its market share.

Q.1 Promoter shareholding and pledge status of Sun Pharma Advanced Research Company Ltd?

Promoters hold 65.67% of the Sun Pharma Advanced Research Company Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Sun Pharma Advanced Research Company Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of -4.2% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	-71.4%	-94.7%	-113.1%	-60%	-179%	-254.1%	-225.6%	-69.4%	-112.9%	-321.2%	-
Value Creation Index ⓘ	-6.3	-8.0	-9.4	-5.3	NA	NA	NA	-6.1	-9.4	NA	-
Growth Parameters ⓘ
Sales ⓘ	161	181	78.3	183	76.8	253	137	239	75.6	71.8	39
Sales YoY Gr.	-	12.2%	-56.8%	133.7%	-58%	229.3%	-45.7%	74%	-68.4%	-5%	-
Adj EPS ⓘ	-3	-4.9	-9.3	-5.5	-12	-5.9	-7.6	-6.9	-12	-10.6	47.8
YoY Gr.	-	NA	NA	NA	NA	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	1.2	6.4	3.7	11.3	-0.7	-6.4	-7.5	15.8	3.9	-6.8	41.1
Adj Net Profit ⓘ	-69.8	-120	-234	-144	-314	-154	-207	-223	-389	-345	1,552
Cash Flow from Ops. ⓘ	-44.2	-128	-183	-172	-211	-152	-208	-69.1	-429	-362	-
Debt/CF from Ops. ⓘ	-1.3	-0	-0	-0	-0.3	-1.5	-0.4	-0	-0.1	-0.7	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-8.6%	-1.4%	-19.4%	-5%
Adj EPS ⓘ	NA	NA	NA	NA
BVPSⓘ	-221.1%	NA	NA	-276.6%
Share Price	-2.6%	-1%	4.2%	31.4%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-106.1	-126.7	-136.6	-60	-226	164.6	301.5	-81.8	-121.9	720	279
Op. Profit Mgn % ⓘ	-39	-67.7	-310	-79.1	-397.7	-53.4	-135.5	-88.7	-530.7	-453.6	4081.4
Net Profit Mgn % ⓘ	-43.3	-66.5	-299.2	-78.9	-408.3	-60.8	-150.5	-93.2	-514.5	-480.4	3964.5
Debt to Equity ⓘ	1.9	0	0	0	-3.6	-1.4	-0.4	0	0.4	-1.2	0
Working Cap Days ⓘ	163	210	641	254	554	175	351	339	1,154	918	3,212
Cash Conv. Cycle ⓘ	-130	-170	-113	-272	-254	-119	-60	-85	-79	-126	509

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	161	181	78	183	77	253	137	239	76	72
Operating Expenses ⓘ +	224	304	321	334	387	388	324	453	479	399
Manufacturing Costs	31	34	37	23	36	214	139	186	146	121
Material Costs	0	0	0	0	0	0	0	0	0	0
Employee Cost	57	84	101	81	93	92	98	107	119	109
Other Costs ⓘ	137	185	183	230	258	82	87	160	214	169
Operating Profit ⓘ	-63	-123	-243	-151	-310	-135	-187	-214	-404	-327
Operating Profit Margin (%)	-39.2%	-67.8%	-310.0%	-82.7%	-403.0%	-53.4%	-136.0%	-89.6%	-534.0%	-456.0%
Other Income ⓘ +	3	14	5	14	10	5	7	11	29	2
Exceptional Items ⓘ	0	0	49	0	0	0	0	0	0	0
Interest ⓘ	2	2	0	0	3	11	13	8	2	9
Depreciation ⓘ	8	8	8	8	9	11	10	12	12	11
Profit Before Tax ⓘ	-70	-119	-197	-145	-312	-151	-203	-223	-388	-345
Tax ⓘ	0	0	0	0	0	0	0	0	0	0
Profit After Tax	-70	-119	-197	-145	-312	-151	-203	-223	-388	-345
PAT Margin (%)	-43.4%	-65.8%	-251.0%	-79.5%	-406.0%	-59.8%	-148.0%	-93.2%	-513.0%	-481.0%
Adjusted EPS (₹)	-3.0	-4.8	-7.9	-5.6	-11.9	-5.8	-7.5	-6.9	-12.0	-10.6
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Sun Pharma Adv. Res - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	30	158	93	296	-19	-168	-203	513	125	-221
Share Capital ⓘ	24	25	25	26	26	26	27	32	32	32
Reserves ⓘ	6	133	68	270	-45	-194	-230	480	92	-253
Debt +	55	3	2	1	66	193	0	0	47	258
Long Term Debt	3	2	2	1	6	113	0	0	0	100
Short Term Debt	52	0	0	0	60	80	0	0	47	158
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	58	94	102	83	159	91	72	148	150	124
Others Liabilities ⓘ	23	21	116	18	66	114	411	169	165	167
Total Liabilities ⓘ	167	277	313	398	273	230	280	830	486	329
Fixed Assets
Net Fixed Assets ⓘ +	70	69	52	58	104	91	92	106	103	95
Gross Block	107	77	67	80	136	123	133	146	152	153
Accumulated Depreciation	37	8	15	23	32	32	41	40	49	57
CWIP ⓘ	1	1	3	24	32	5	26	27	44	54
Investments ⓘ	0	10	108	211	8	6	12	291	2	0
Inventories	0	0	0	0	0	0	0	0	0	0
Trade Receivables	9	39	18	10	16	18	28	33	16	16
Cash Equivalents ⓘ	13	70	1	1	0	9	1	112	155	1
Others Assets ⓘ	74	87	131	95	112	101	121	262	167	162
Total Assets ⓘ	167	277	313	398	273	230	280	830	486	329

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-44	-128	-183	-172	-211	-152	-208	-69	-429	-362
PBT ⓘ	-70	-119	-246	-145	-312	-151	-203	-223	-388	-345
Adjustment ⓘ	9	-1	4	-22	9	49	17	7	-11	19
Changes in Working Capital ⓘ	30	13	20	-0	102	-48	-26	141	-26	-47
Tax Paid ⓘ	-14	-21	-10	-5	-10	-2	5	5	-4	11
Cash Flow From Investing Activity ⓘ +	-13	-7	-105	-102	155	2	-29	-548	391	158
Capex	-12	-8	-18	-13	-54	-1	-25	-15	-26	-10
Net Investments	-0	-9	-88	-93	209	3	-5	-535	395	153
Others ⓘ	-1	11	1	3	0	0	0	2	22	15
Cash Flow From Financing Activity ⓘ +	51	194	224	274	55	159	229	617	43	201
Net Proceeds from Shares ⓘ	2	250	133	367	-0	0	167	0	0	0
Net Proceeds from Borrowing ⓘ	-1	-1	0	-1	0	106	-113	0	0	100
Interest Paid ⓘ	-2	-3	-0	-0	-2	-8	-14	-8	-2	-8
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	51	-52	91	-92	57	61	189	625	44	109
Net Cash Flow ⓘ	-7	60	-63	0	0	9	-8	-1	4	-4

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	-109.16	-127.4	-156.84	-74.72	N/A	N/A	N/A	-143.72	-121.73	N/A
ROCE (%)	-71.37	-94.66	-113.05	-59.95	N/A	N/A	N/A	-69.44	-112.88	N/A
Asset Turnover Ratio	1.03	0.82	0.27	0.51	0.23	1.01	0.54	0.43	0.11	0.18
PAT to CFO Conversion(x)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	32.90	48.50	131.70	27.70	62.30	24.30	60.30	46.20	116.60	80.30
Inventory Days	0	0	0	0	0	0	0	0	0	0
Payable Days	0	0	0	0	0	0	0	0	0	0

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

2.78

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Sun Pharma Advanced Research Company Ltd FAQs

The current trading price of Sun Pharma Adv. Res on 04-Jun-2026 16:59 is ₹212.9.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Sun Pharma Adv. Res stood at ₹6,909.1 Cr

The latest P/E ratio of Sun Pharma Adv. Res as of 03-Jun-2026 is 4.45.

The latest P/B ratio of Sun Pharma Adv. Res as of 03-Jun-2026 is 5.18.

The 52-week high of Sun Pharma Adv. Res is ₹248.7 and the 52-week low is ₹108.2.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sun Pharma Adv. Res is ₹39.15 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Sun Pharma Advanced Research Company Ltd is a below average quality company.

The key valuation ratios of Sun Pharma Advanced Research Company Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Sun Pharma Advanced Research Company Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company (SPARC) is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. SPARC was formed in 2007 through a demerger from SUN PHARMA, a global leader in speciality generics. It strive to build an enduring innovation engine built on strong scientific execution, high value analytics and aggressive portfolio management. A robust mix of internal ideation and strategic partnering with academic innovators and bio-pharma entrepreneurs fuel engine with potentially high impact ideas.

The company partner with thought-leading clinicians across the world for ideas and access. Innovation through integration of partner knowledge and efficient internal execution shapes future. SPARC is a vibrant innovation community spread over three locations globally. It endeavour to develop a meritocracy which takes pride in continuous learning and re-invention. SPARC is a responsible public company committed to maintaining highest standards of ethics and transparency.

Business area of the company

The company is engaged in the pharmaceutical research and development. The company’s core focus is innovation and new product development for global markets. SPARC undertakes projects in research and technology for new chemical entities (NCE’s) or new molecules, and novel drug delivery systems (NDDS).

Products

Therapeutic Focus (Oncology, Neuro Degeneration, Ophthalmology, Dermatology)
Delivery Technologies (Gastro Retentive Innovative Device, Wrap Matrix, Abuse Deterrent Program, Nanotecton Technology, Dry Powder Inhalation, TearAct, Lipixelle, Gel Free Reservoir)
Research Programs (Taclantis, SCO - 088, SCD - 044, SCC - 138, SCO - 120)

Milestones

2006: SPARC is founded in Vadodara, India
2007: Innovative R&D business was demerged from Sun Pharmaceutical Industries Limited to focus on innovative drug research
2007: Listed on Bombay Stock Exchange and National Stock Exchange of India
2012: 1st NDA filed with USFDA for Elepsia XR
2012: Raised Rs. 200 crore through Rights Issue
2013: Filed NDA for Xelpros with USFDA
2014: US rights for Xelpros licensed to a subsidiary of Sun Pharma
2015: Entered into research collaboration in the field of Oncology with US University
2015: Launched Bevetex (PICS) in India
2016: Raised Rs. 250 crore through Rights Issue
2017: Secured funding of up to Rs. 500 crore through Preferential Allotment of warrants convertible into equity shares
2018: Entered into collaboration with Schrödinger to accelerate Neurodegeneration Drug Development Programs
2018: Positive top line results reported for the pivotal bioequivalence study of Taclantis (Paclitaxel Injection Concentrate for Suspension)
2018: US FDA approved Xelpros for the treatment of open-angle glaucoma or ocular hypertension
2019: Entered into licensing agreement with Bioprojet SCR to acquire exclusive rights for Investigational Medicinal Product, SCD-044
2019: Entered into a licensing deal with China Medical System Holdings Limited (CMS) to develop and commercialize multiple products in Mainland China, Hong Kong, Macao, and Taiwan
2019: Orphan Drug Designation received from the US FDA for SPARCs neonatal seizures drug, Phenobarbital
2019: Orphan Drug Designation received from the US FDA for SPARCs Chronic Myeloid Leukemia drug, SCO-088
2019: NDA for Taclantis (Paclitaxel Injection Concentrate for Suspension) accepted by US FDA for review
2019: Entered into collaboration with HitGen for Innovative Drug Discovery Research
2020: Entered into a worldwide license agreement for SCD-044 with Sun Pharma
2020: Entered into collaboration with the University of Michigan to kickstart research and development of potential new medications

Sun Pharma Advanced Research Company Ltd (SPARC)

Sun Pharma Advanced Research Company Ltd (SPARC)

Sun Pharma Advanced Research Company stock performance